Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C treatment

    Effective direct-acting antiviral or 'DAA' medicines, used without interferon, can now cure most people with hepatitis C. This includes people who previously were considered to be more difficult...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    DAAs target different steps of HCV reproduction. These include HCV protease inhibitors, polymerase inhibitors and NS5A inhibitors. Recommended regimens include at least two drugs that work in different...

    From: Booklets

    Information level Level 2
  • Treatment for people with HIV and HCV co-infection

    In the UK, standards for HIV treatment and care are set and monitored by the British HIV Association (BHIVA), the professional association for HIV doctors and other healthcare...

    From: Booklets

    Information level Level 2
  • Hepatitis C and HIV

    Hepatitis C is a blood-borne infection that is transmitted in some of the same ways as HIV.Over time untreated hepatitis C...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • EATG launches a report on access to HCV-related services in the penitentiary system in Europe

    Drawing on research on the state of access to services related to Hepatitis C in prison settings in Europe and Central Asia, which has highlighted major shortcomings across the countries as well as some promising practices in few countries, the European AIDS Treatment Group calls on national and prison authorities to scale up access to voluntary and confidential testing and counselling for people in detention.

    23 May 2018 | EATG
  • Do direct acting antivirals cure chronic hepatitis C?

    We were dismayed that the Editors of the BMJ presented the widely discredited Cochrane review of Hepatitis C virus therapy as mainstream opinion. It is not... There is no credible explanation for the fall in hepatitis C liver disease morbidity and mortality associated with the introduction of effective anti-virals other than the use of these drugs.

    18 May 2018 | BMJ
  • How states could be saving more hepatitis C patients

    USC’s Neeraj Sood and colleagues propose an approach that leverages competition among drug manufacturers, saving states money and ensuring that more people get treatment

    15 May 2018 | USC News
  • Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents

    Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need.

    14 May 2018 | Intellectual Property Watch
  • Gilead Topples As Its Hepatitis C Drug Franchise Continues To Crumble

    Sales of hepatitis C drugs Harvoni, Sovaldi and Epclusa raked in $1.05 billion, declining 59%. That was the single biggest year-over-year decline in the eight quarters since Gilead started reporting sales of hepatitis C drugs separately from its other antiviral products.

    02 May 2018 | Investor's Business Daily
  • Many European countries are not ready to stop viral hepatitis

    Many European countries lack a comprehensive policy to eliminate viral hepatitis as a major public health threat, according to a patient group-based survey implemented in 25 countries. The Hep-CORE study was coordinated by ISGlobal - an institution supported by the "la Caixa" Foundation - and led by the European Liver Patient's Association.

    19 April 2018 | Eurekalert Medicine & Health
  • Linkage to care specialist facilitates access to hepatitis C treatment for people who inject drugs

    A longitudinal study involving more than 1,000 individuals reports promising role for linkage to care specialists in expanding access to hepatitis C treatment for people who inject drugs. Almost 50% of patients referred to a medical practitioner made it to their first appointment and that 60% of those seen were initiated on treatment.

    13 April 2018 | Eurekalert Inf Dis
  • How Well Do Docs Manage Potential Conflicts Between Hep C and HIV Meds?

    A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

    10 April 2018 | Poz
  • Newly Discovered HCV Subtype is Resistant to Antiviral Treatment

    A newly discovered hepatitis C virus (HCV) genotype 1 subtype harbors multiple resistance-associated mutations that combine to block therapeutic effect of NS5A inhibitor direct-acting antivirals (DAAs).

    21 March 2018 | MD Magazine
  • Study: Shorter hepatitis C treatment effective in black patients

    An eight-week treatment regimen for hepatitis C is just as effective as the recommended 12 weeks in African-American patients, according to a Harvard study.

    16 March 2018 | UPI.com
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.